Mereo BioPharma Group plc

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

MREO$0.30+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets

	December 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$40,992	$69,802
Prepaid expenses and other current assets	2,531	2,175
Research and development incentives receivables	1,497	2,786
Total current assets	45,020	74,763
Property and equipment, net	137	257
Operating lease right-of-use assets, net	244	727
Intangible assets, net	516	643
Total assets	$45,917	$76,390
Liabilities
Current liabilities:
Accounts payable	$1,333	$2,440
Accrued expenses	2,026	4,071
Convertible loan notes – current	—	5,535
Operating lease liabilities – current	202	707
Other current liabilities	741	1,095
Total current liabilities	4,302	13,848
Warrant liabilities – non-current	38	821
Operating lease liabilities – non-current	—	187
Other non-current liabilities	661	565
Total liabilities	$5,001	$15,421
Commitments and contingencies (Note 17)
Shareholders’ Equity
Ordinary shares, par value £0.003 per share; 795,658,504 shares issued at December 31, 2025 (December 31, 2024: 775,728,034)	$3,135	$3,059
Additional paid-in capital	549,622	539,642
Accumulated deficit	(501,018)	(462,883)
Accumulated other comprehensive loss	(10,823)	(18,849)
Total shareholders’ equity	40,916	60,969
Total liabilities and shareholders’ equity	$45,917	$76,390

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.